Sign up online today & collaborate
or click here to find out more
Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of under-served immune-regulated conditions, today announced that the U.S. Magistrate Judge in the Company’s patent infringement lawsuit against Qiagen, Inc., Quest Diagnostics, Inc. and Laboratory Corporation of America Holdings has issued a recommendation denying in substantial part the defendants’ motion to dismiss the Company’s claims. In issuing his recommendation, the magistrate judge stated, “At this early juncture, the Court concludes that the in vitro aspect of the plaintiff’s tuberculosis test is an ‘inventive concept’ because it improves on prior methods of detecting tuberculosis infection.” The magistrate judge’s recommendation should now allow the Company to press forward with its case against the three defendants, asserting infringement of its six patents relating to methods for diagnosing TB infection.
“We are encouraged by the magistrate judge’s recommendation as it affirms our belief that Qiagen’s TB tests, as well as the laboratories performing those tests, are infringing our patented intellectual property,” said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. “We look forward to vigorously prosecuting our claims based upon our six patents through the next phases of discovery and trial.”
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of under-served immune-regulated conditions.
The Company’s first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The company’s second product line is a range of assays for Tick-borne diseases, such as Lyme disease, obtained through the acquisition of Imugen, Inc in July 2016.
The T-SPOT.CMV test and the T-SPOT.PRT test are the Company’s third and fourth products and part of a series of assays intended for the transplantation market. In addition to these four product lines, the Company has additional active development programs, each of which leverages our proprietary immunology platforms. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
For Media Inquiries:
Tel: +44 1235 442796
For Investor Inquiries:
Chief Financial Officer
Tel: +1 (508) 573-9953
Tel: +1 (443) 213-0501